Solventum (NYSE:SOLV) Issues FY 2025 Earnings Guidance

Solventum (NYSE:SOLV) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 5.450-5.650 for the period, compared to the consensus EPS estimate of 5.490. The company issued revenue guidance of -.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on SOLV. Piper Sandler upped their price target on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research note on Friday, November 8th. Morgan Stanley upped their price target on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Mizuho started coverage on Solventum in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price objective on the stock. Finally, Bank of America increased their price target on Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $71.86.

Solventum Stock Down 0.7 %

Shares of NYSE SOLV traded down $0.58 during midday trading on Thursday, reaching $83.46. The company’s stock had a trading volume of 1,496,909 shares, compared to its average volume of 1,000,142. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. Solventum has a fifty-two week low of $47.16 and a fifty-two week high of $96.05. The business’s 50 day moving average price is $71.92 and its two-hundred day moving average price is $69.63.

Solventum (NYSE:SOLV) last announced its quarterly earnings data on Thursday, February 27th. The company reported $1.41 EPS for the quarter, beating the consensus estimate of $1.31 by $0.10. On average, equities analysts forecast that Solventum will post 6.58 EPS for the current fiscal year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.